Fig. 9: ERBB2 inhibition combined with anti-PD-1 display synergistic treatment effects in SCLC mice.

a Serial µCT measurements of one representative mouse per therapy group. Target lesion diameter is marked in red. H, heart; cross (hand-drawn), dead. b OS was determined in the four therapy groups (log-rank (Mantel–Cox) test; vehicle n = 18; anti-PD-1 n = 16; ERBB2i (mubritinib) n = 10; anti-PD-1 + ERBB2i (mubritinib) n = 13). c PFS determined in the four therapy groups (log-rank (Mantel–Cox) test; vehicle n = 14; anti-PD-1 n = 10; ERBB2i (mubritinib) n = 10; anti-PD-1 + ERBB2i (mubritinib) n = 13). d Change in target lesion diameter calculated from all therapy groups after some weeks of treatment. PD, SD, and PR according to described mouse-adapted RECIST v1.1 criteria. e Pie chart representing the quantification of liver metastases after vehicle, anti-PD-1, ERBB2i or anti-PD-1 + ERBB2i treatment. f MHC-I expression determined by FACS analysis from lung of mice of the different treatment groups (two-sided Mann–Whitney test, vehicle n = 13, anti-PD-1 n = 10, ERBB2i n = 6, anti-PD-1 + ERBB2i n = 6; error bars, mean ± SEM). g Schematic representation of the analysis of different therapy groups in publicly available scRNA-seq data from SCLC patient tumors¹⁰. Created in BioRender. Meder, L. (2025) https://BioRender.com/vkn5pfz. h Dot plot of markers in different therapy groups in publicly available scRNA data set. *p  <  0.05, **p  <  0.01, ***p < 0.001. Source data are provided as a Source Data file.